The finger displacement sign is a simple bedside test that can help distinguish Parkinson dementia from Alzheimer dementia.
New research highlights the need for early identification of traumatic brain injury as well as an interdisciplinary approach to determining treatment strategies.
A new class of injectable monoclonal antibodies directed against calcitonin gene related peptide (CGRP) or its receptor may offer hope to migraineurs who have not found effective prophylactic therapy.
Noninvasive neuromodulation therapy shows promise in treating hand tremors associated with essential tremor.
Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.
EULAR 20017: Despite the use of biologic therapy, pain ranging from mild to severe is a persistent problem for psoriatic arthritis patients, researchers reported at EULAR 2017.
Studies examined the impact of blood pressure trajectories on dementia risk and explored the relationship between sleep apnea and Aβ accumulations.
Highlights: imaging the temporal dynamics & cellular architecture of seizures in Dravet syndrome, & reducing risk of spontaneous fetal loss.
Blood protein analysis of plasma total tau has diagnostic use in Alzheimer disease. Could the same hold true for CTE?
The effect of blood pressure on IAT safety and benefit and pediatric stroke outcomes based on treatment were some of the studies presented at AAN.